ALC logo

Alcon Inc. Stock Price

SWX:ALC Community·CHF 25.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author

ALC Share Price Performance

CHF 51.72
-18.00 (-25.82%)
CHF 88.89
Fair Value
CHF 51.72
-18.00 (-25.82%)
41.8% undervalued intrinsic discount
CHF 88.89
Fair Value
Price CHF 51.72
AnalystHighTarget CHF 88.89
AnalystConsensusTarget CHF 79.02
AnalystLowTarget CHF 60.81

ALC Community Narratives

·
Fair Value CHF 88.89 41.8% undervalued intrinsic discount

Unity VCS And LumiThera Will Drive Global Eye Care Transformation

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value CHF 79.02 34.5% undervalued intrinsic discount

Cutting Edge Eye Care Solutions Will Transform Outcomes For Global Aging Populations

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
·
Fair Value CHF 60.81 15.0% undervalued intrinsic discount

Government Price Cuts Will Compress Margins Though Telemedicine Supports

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CHF 88.89
41.8% undervalued intrinsic discount
Revenue
7.6% p.a.
Profit Margin
15.4%
Future PE
29.81x
Price in 2029
CHF 101.9
CHF 60.81
15.0% undervalued intrinsic discount
Revenue
6.1% p.a.
Profit Margin
12.48%
Future PE
26.91x
Price in 2029
CHF 70.32

Trending Discussion

Updated Narratives

ALC logo

ALC: Share Buybacks And New Eye Care Launches Will Support Upside

Fair Value: CHF 88.89 41.8% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ALC logo

ALC: Contact Lens Expansion And Patent Royalties Will Shape Measured Outlook

Fair Value: CHF 60.81 15.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ALC logo

ALC: New Lens Launches And Share Buybacks Will Support Future Outperformance

Fair Value: CHF 79.02 34.5% undervalued intrinsic discount
20 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

1 Risk
3 Rewards

Alcon Inc. Key Details

US$10.6b

Revenue

US$4.7b

Cost of Revenue

US$5.9b

Gross Profit

US$5.1b

Other Expenses

US$819.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 11, 2026
1.68
55.78%
7.70%
21.4%
View Full Analysis

About ALC

Founded
1945
Employees
25000
CEO
David Endicott
WebsiteView website
www.alcon.com

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Recent ALC News & Updates

Narrative Update May 19

ALC: Share Buybacks And New Eye Care Launches Will Support Upside

Analysts now estimate Alcon's fair value at CHF 88.89, reduced from CHF 92.41, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Board of Directors authorized a share repurchase program of up to US$1,500 million.

Recent updates

No updates